share_log

Universe Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

Universe Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

大自然藥業 | 6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/12/13 05:36

Moomoo AI 已提取核心訊息

Universe Pharmaceuticals has entered into a securities purchase agreement on December 6, 2024, to raise $15 million through a registered direct offering. The offering includes 388,000 ordinary shares, 18.36 million pre-funded warrants, and 18.75 million common warrants, priced at $0.80 per share and warrant combination, or $0.79 per pre-funded warrant and warrant combination.The offering closed on December 10, 2024, with Univest Securities serving as the exclusive placement agent, receiving a 7% fee of gross proceeds plus additional fees. The company plans to utilize the net proceeds for marketing activities, production capacity expansion, and general corporate purposes.The securities were offered under the company's effective F-3 registration statement, which was declared effective by the SEC on November 15, 2022. The common warrants have a 5-year term with an exercise price of $0.80 per share, while the pre-funded warrants have an exercise price of $0.001 per share.
Universe Pharmaceuticals has entered into a securities purchase agreement on December 6, 2024, to raise $15 million through a registered direct offering. The offering includes 388,000 ordinary shares, 18.36 million pre-funded warrants, and 18.75 million common warrants, priced at $0.80 per share and warrant combination, or $0.79 per pre-funded warrant and warrant combination.The offering closed on December 10, 2024, with Univest Securities serving as the exclusive placement agent, receiving a 7% fee of gross proceeds plus additional fees. The company plans to utilize the net proceeds for marketing activities, production capacity expansion, and general corporate purposes.The securities were offered under the company's effective F-3 registration statement, which was declared effective by the SEC on November 15, 2022. The common warrants have a 5-year term with an exercise price of $0.80 per share, while the pre-funded warrants have an exercise price of $0.001 per share.
大自然藥業於2024年12月6日簽署了一份證券購買協議，計劃通過一次註冊的直接發行籌集1500萬美元。這次發行包括388,000股普通股，1836萬份預先融資Warrants和1875萬份普通Warrants，價格爲每股和Warrant組合0.80美元，或者每份預先融資Warrant和Warrant組合0.79美元。此次發行於2024年12月10日完成，由Univest Securities擔任獨家Placement Agent，收取7%的毛收益費用及額外費用。公司計劃將淨收益用於市場推廣活動、生產能力擴展和一般公司用途。這些證券是在公司有效的F-3註冊聲明下提供的，該聲明於2022年11月15日被美國證券交易委員會批准。普通Warrant的有效期爲5年，行使價格爲每股0.80美元，而預融資Warrant的行使價格爲每股0.001美元。
大自然藥業於2024年12月6日簽署了一份證券購買協議，計劃通過一次註冊的直接發行籌集1500萬美元。這次發行包括388,000股普通股，1836萬份預先融資Warrants和1875萬份普通Warrants，價格爲每股和Warrant組合0.80美元，或者每份預先融資Warrant和Warrant組合0.79美元。此次發行於2024年12月10日完成，由Univest Securities擔任獨家Placement Agent，收取7%的毛收益費用及額外費用。公司計劃將淨收益用於市場推廣活動、生產能力擴展和一般公司用途。這些證券是在公司有效的F-3註冊聲明下提供的，該聲明於2022年11月15日被美國證券交易委員會批准。普通Warrant的有效期爲5年，行使價格爲每股0.80美元，而預融資Warrant的行使價格爲每股0.001美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    坎伯蘭藥業
    CPIX
    -- 6.050
    Esperion Therapeutics
    ESPR
    -- 1.770
    Evoke Pharma
    EVOK
    -- 3.9600
    OptiNose
    OPTN
    -- 5.620
    Indivior
    INDV
    -- 10.100
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！